Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a report issued on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

Shares of Pieris Pharmaceuticals stock opened at $13.60 on Thursday. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The firm has a market capitalization of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. The stock has a 50 day moving average of $15.59 and a 200 day moving average of $14.88.

Institutional Trading of Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals comprises about 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st largest position. BML Capital Management LLC owned 3.19% of Pieris Pharmaceuticals as of its most recent SEC filing. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.